Cargando…
Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy
The development of stable and long-circulating liposomes provides protection of the drug cargo from degradation and increases tumor drug delivery, leading to the design of liposome formulations with great potential in cancer therapy. However, despite the sound pharmacologic basis, many liposomal as...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382151/ https://www.ncbi.nlm.nih.gov/pubmed/28428790 http://dx.doi.org/10.3389/fimmu.2017.00416 |
_version_ | 1782520045185794048 |
---|---|
author | La-Beck, Ninh M. Gabizon, Alberto A. |
author_facet | La-Beck, Ninh M. Gabizon, Alberto A. |
author_sort | La-Beck, Ninh M. |
collection | PubMed |
description | The development of stable and long-circulating liposomes provides protection of the drug cargo from degradation and increases tumor drug delivery, leading to the design of liposome formulations with great potential in cancer therapy. However, despite the sound pharmacologic basis, many liposomal as well as other nanoparticle-based drug formulations have failed to meet regulatory criteria for approval. The question that arises is whether we have missed key liposome–host interactions that can account for the gap between the major pharmacologic advantages in preclinical studies and the modest impact of the clinical effects in humans. We will discuss here the nanoparticle–immune system interactions that may undermine the antitumor effect of the nanodrug formulations and contribute to this gap. To overcome this challenge and increase clinical translation, new preclinical models need to be adopted along with comprehensive immunopharmacologic studies and strategies for patient selection in the clinical phase. |
format | Online Article Text |
id | pubmed-5382151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53821512017-04-20 Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy La-Beck, Ninh M. Gabizon, Alberto A. Front Immunol Immunology The development of stable and long-circulating liposomes provides protection of the drug cargo from degradation and increases tumor drug delivery, leading to the design of liposome formulations with great potential in cancer therapy. However, despite the sound pharmacologic basis, many liposomal as well as other nanoparticle-based drug formulations have failed to meet regulatory criteria for approval. The question that arises is whether we have missed key liposome–host interactions that can account for the gap between the major pharmacologic advantages in preclinical studies and the modest impact of the clinical effects in humans. We will discuss here the nanoparticle–immune system interactions that may undermine the antitumor effect of the nanodrug formulations and contribute to this gap. To overcome this challenge and increase clinical translation, new preclinical models need to be adopted along with comprehensive immunopharmacologic studies and strategies for patient selection in the clinical phase. Frontiers Media S.A. 2017-04-06 /pmc/articles/PMC5382151/ /pubmed/28428790 http://dx.doi.org/10.3389/fimmu.2017.00416 Text en Copyright © 2017 La-Beck and Gabizon. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology La-Beck, Ninh M. Gabizon, Alberto A. Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy |
title | Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy |
title_full | Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy |
title_fullStr | Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy |
title_full_unstemmed | Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy |
title_short | Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy |
title_sort | nanoparticle interactions with the immune system: clinical implications for liposome-based cancer chemotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382151/ https://www.ncbi.nlm.nih.gov/pubmed/28428790 http://dx.doi.org/10.3389/fimmu.2017.00416 |
work_keys_str_mv | AT labeckninhm nanoparticleinteractionswiththeimmunesystemclinicalimplicationsforliposomebasedcancerchemotherapy AT gabizonalbertoa nanoparticleinteractionswiththeimmunesystemclinicalimplicationsforliposomebasedcancerchemotherapy |